Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:BTMDNASDAQ:CUENASDAQ:SOPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$9.11-2.7%$9.78$7.08▼$20.60$187.07M1.3872,691 shs115,140 shsBTMDbiote$3.30-0.3%$3.92$3.04▼$8.44$180.54M1.17186,781 shs108,305 shsCUECue Biopharma$0.76-2.2%$1.01$0.45▼$2.26$47.11M2.02443,926 shs111,540 shsSOPHSOPHiA GENETICS$2.83+0.7%$3.31$2.60▼$6.28$188.72M1.0265,444 shs19,163 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin0.00%-2.04%-0.98%-18.37%-50.33%BTMDbiote0.00%-9.59%-21.80%-41.49%-40.22%CUECue Biopharma0.00%-0.54%-21.38%-41.83%-53.25%SOPHSOPHiA GENETICS0.00%-1.74%-5.67%-9.29%-41.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.2462 of 5 stars1.02.00.00.02.20.00.0BTMDbiote3.2701 of 5 stars3.52.00.00.03.73.31.3CUECue Biopharma4.3213 of 5 stars3.54.00.04.72.90.81.3SOPHSOPHiA GENETICS1.6056 of 5 stars3.43.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-23.16% DownsideBTMDbiote 3.00Buy$8.00142.42% UpsideCUECue Biopharma 3.00Buy$3.00293.70% UpsideSOPHSOPHiA GENETICS 2.75Moderate Buy$6.80140.28% UpsideCurrent Analyst Ratings BreakdownLatest CUE, AMRN, BTMD, and SOPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.003/6/2025SOPHSOPHiA GENETICSBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$5.00(Data available from 4/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M0.82N/AN/A$1.35 per share6.75BTMDbiote$197.19M0.92$0.34 per share9.60($0.58) per share-5.69CUECue Biopharma$9.29M5.07N/AN/A$0.82 per share0.93SOPHSOPHiA GENETICS$65.17M2.90N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$4.00N/AN/AN/A-16.33%-7.22%-4.96%5/7/2025 (Estimated)BTMDbiote$3.32M$0.1812.696.11N/A5.20%-32.41%22.26%5/6/2025 (Estimated)CUECue Biopharma-$50.73M-$0.75N/AN/AN/A-468.02%-156.38%-88.07%5/8/2025 (Estimated)SOPHSOPHiA GENETICS-$78.98M-$0.95N/AN/AN/A-110.71%-55.06%-38.33%5/6/2025 (Estimated)Latest CUE, AMRN, BTMD, and SOPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CUECue Biopharma-$0.15N/AN/AN/A$0.90 millionN/A5/7/2025Q1 2025AMRNAmarin-$0.06N/AN/AN/AN/AN/A5/6/2025Q1 2025BTMDbiote$0.06N/AN/AN/A$47.25 millionN/A5/6/2025Q1 2025SOPHSOPHiA GENETICS-$0.21N/AN/AN/A$16.76 millionN/A3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/4/2025Q4 2024SOPHSOPHiA GENETICS-$0.23-$0.23N/A-$0.23$17.71 million$17.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ABTMDbioteN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/ASOPHSOPHiA GENETICSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11BTMDbioteN/A1.501.16CUECue Biopharma0.052.222.22SOPHSOPHiA GENETICS0.123.803.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%BTMDbiote21.68%CUECue Biopharma35.04%SOPHSOPHiA GENETICS31.59%Insider OwnershipCompanyInsider OwnershipAMRNAmarin1.96%BTMDbiote24.00%CUECue Biopharma12.26%SOPHSOPHiA GENETICS4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.53 million402.62 millionOptionableBTMDbiote19454.71 million46.78 millionNot OptionableCUECue Biopharma6061.82 million55.58 millionOptionableSOPHSOPHiA GENETICS52066.69 million62.19 millionNot OptionableCUE, AMRN, BTMD, and SOPH HeadlinesRecent News About These CompaniesSophia Genetics, Precision for Medicine enter strategic partnershipApril 9, 2025 | markets.businessinsider.comPrecision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy CapabilitiesApril 8, 2025 | prnewswire.comSOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest UpdateApril 1, 2025 | marketbeat.comSOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?March 21, 2025 | zacks.comMorgan Stanley Keeps Their Hold Rating on SOPHiA GENETICS (SOPH)March 20, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from BTIGMarch 18, 2025 | markets.businessinsider.comSOPHiA GENETICS Announces Two Million Patient Cases Analyzed, Marking a New Milestone for Data-Driven Medicine at NVIDIA GTCMarch 18, 2025 | prnewswire.comSOPHiA GENETICS (SOPH) Receives a Buy from BTIGMarch 12, 2025 | markets.businessinsider.comBaby Sophia from embryo swap will stay with birth parents court rules on appealMarch 11, 2025 | msn.comDistrict Court rules to keep IVF child with birth mother following embryo mix-upMarch 10, 2025 | msn.comCourt overturns ruling that ordered toddler returned to genetic parents following embryo mix-upMarch 10, 2025 | msn.comSophia Genetics price target lowered to $5 from $6 at BTIGMarch 6, 2025 | markets.businessinsider.comSOPHiA GENETICS (SOPH) Gets a Buy from RBC CapitalMarch 5, 2025 | markets.businessinsider.comSOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comSOPHiA GENETICS Full Year 2024 Earnings: In Line With ExpectationsMarch 5, 2025 | finance.yahoo.comSOPHiA GENETICS SA (SOPH) Q4 2024 Earnings Call TranscriptMarch 4, 2025 | seekingalpha.comSophia Genetics sees FY25 revenue $72M-$76M, consensus $74.51MMarch 4, 2025 | markets.businessinsider.comCraig-Hallum Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH)March 4, 2025 | markets.businessinsider.comSOPHiA GENETICS SA (SOPH) Reports Q4 Loss, Tops Revenue EstimatesMarch 4, 2025 | zacks.comSOPHiA GENETICS Reports Fourth Quarter and Full Year 2024 ResultsMarch 4, 2025 | prnewswire.comSOPHiA GENETICS: Leading Healthcare Institutions Adopt MSK-ACCESS for Liquid Biopsy TestingFebruary 24, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Are Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military Spending5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatNew Tariffs May Bring Liberation to These 3 Steel StocksBy Gabriel Osorio-Mazilli | April 7, 2025View New Tariffs May Bring Liberation to These 3 Steel StocksCUE, AMRN, BTMD, and SOPH Company DescriptionsAmarin NASDAQ:AMRN$9.11 -0.25 (-2.67%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$9.38 +0.27 (+2.96%) As of 04/17/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.biote NASDAQ:BTMD$3.30 -0.01 (-0.30%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.40 +0.10 (+3.03%) As of 04/17/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Cue Biopharma NASDAQ:CUE$0.76 -0.02 (-2.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.74 -0.02 (-2.23%) As of 04/17/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.SOPHiA GENETICS NASDAQ:SOPH$2.83 +0.02 (+0.71%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.86 +0.02 (+0.88%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
